Vertex receives chmp positive opinion for expanded label for kaftrio® in combination with ivacaftor for people with cystic fibrosis to include rare mutations

London--(business wire)--vertex pharmaceuticals (nasdaq: vrtx) today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) adopted a positive opinion for the label expansion of kaftrio® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor for the treatment of people with cystic fibrosis (cf) aged 2 years and older who have at least one non-class i mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene. “we.
VRTX Ratings Summary
VRTX Quant Ranking